HSBC maintains a Buy rating on Gilead Sciences; PT raised to $175
Benzinga/TradingView data show HSBC raised its Gilead Sciences price target to $175.00 a share from $155.00 while maintaining a Buy rating. The action is attributed to HSBC.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.